Clinical Trial Update: Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating plerixafor (AMD3100) as a stem cell mobilizer for transplantation from a sibling donor in various hematologic malignancies; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Hodgkin Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma

Drugs mentioned

• Plerixafor (Mozobil) (plerixafor)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-06-06